Search | Clinical Trials Finder

Conditions: Prostate Cancer, Cardiovascular Death
Interventions: No intervention was required; Other
Lead sponsor: Prostate Cancer Foundation of Chicago; Other
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Westmont, Illinois

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Testicular Cancer
Interventions: Acceptance and Commitment Therapy (ACT) Coaching, Education and Support Coaching; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: azacitidine for injectable suspension; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 13
States / cities: Denver, Colorado • Ocoee, Florida • Minneapolis, Minnesota + 10 more

Conditions: Healthy
Interventions: Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: atrasentan hydrochloride, docetaxel, prednisone, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 554
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more

Conditions: Prostate Cancer
Interventions: Standard of Care; Other
Lead sponsor: Prostate Cancer Clinical Trials Consortium; Other
Eligibility: 21 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 48
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 1 Month to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hyperoxaluria, Primary
Interventions: Oxabact OC5 - Oxalobacter formigenes Strain HC-1; Biological
Lead sponsor: OxThera; Industry
Eligibility: 3 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: JNJ-54452840, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Ovarian Neoplasms
Interventions: removal of ovarian vessels; Procedure
Lead sponsor: United States Department of Defense; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Weight Loss, Fecal Incontinence, Bariatric Surgery, glp1 Agonist
Interventions: Bariatric Surgery, GLP1 receptor agonist; Procedure · Drug
Lead sponsor: Hartford HealthCare; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma

Conditions: Overweight and Obesity, Weight Loss
Interventions: Time restricted feeding, Normal feeding; Other
Lead sponsor: Kyle Hackney; Other
Eligibility: 35 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Prostate Cancer
Interventions: Relugolix, Leuprolide Acetate; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Tucson, Arizona • Orange, California • Denver, Colorado + 24 more

Conditions: Prostate Cancer
Interventions: Docetaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more

Conditions: Renal Impairment
Interventions: LIK066; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Low Libido
Interventions: Flibanserin, Placebo; Drug
Lead sponsor: Mohit Khera; Other
Eligibility: 18 Years to 69 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions: MCI-196, Placebo; Drug
Lead sponsor: Tanabe Pharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Glendale, Arizona • Tempe, Arizona • Hot Springs, Arkansas + 35 more

Conditions: Chronic Kidney Failure
Interventions: Fermagate, Sevelamer hydrochloride; Drug
Lead sponsor: Ineos Healthcare Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 40
States / cities: Hot Springs, Arkansas • Bakersfield, California • Lynwood, California + 32 more

Conditions: Turner Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 2 Weeks to 2 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: Computerized patient decision-aid, Usual care (lupus pamphlet); Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pelvic Floor Muscle Weakness, Pelvic Floor Disorder, Pelvic Pain, Hip Strength
Interventions: Not listed
Lead sponsor: George Fox University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newberg, Oregon

Search by objective public record fields.

Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Pursuing Exploration Into the Supportive Care Needs and Intervention Preferences of Survivors of Testicular Cancer

Vidaza to Restore Hormone Thx Prostate

Cefadroxil 500 mg Capsules Under Fasting Conditions

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Effect of Cumulative Chloride Dose on Development of Acute Kidney Injury in Critically Ill Children

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Exercise Training and Time-restricted Feeding in Overweight and Obese Adults

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Hypoactive Sexual Desire Disorder in Males

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

Does Hip Strength Impact Active Females Rate of Pelvic Floor Dysfunction? The Primary Goal of This Research is to Collect Data on Hip Strength for Active Females and Assess if There is a Relationship Between Hip Strength and Pelvic Floor Dysfunction (PFD).